TY - JOUR T1 - Response to: ‘Belimumab and the measurement of fatigue’ by Mazzoni JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - e54 LP - e54 DO - 10.1136/annrheumdis-2015-207700 VL - 74 IS - 9 AU - V Strand AU - R A Levy AU - R Cervera AU - M Petri Y1 - 2015/09/01 UR - http://ard.bmj.com/content/74/9/e54.abstract N2 - We agree that fatigue is a common and important symptom of patients with active systemic lupus erythematosus (SLE), and that it is multidimensional, as has been elegantly described in patients with rheumatoid arthritis.1 In fact, randomised controlled trials in SLE have assessed fatigue, as early as the prasterone dehydroepiandrosterone (DHEA) studies (published in 2002–2004) that employed the (Krupp) Fatigue Severity Scale (FSS), developed … ER -